Friday, March 4, 2022
12:30 PM – 1:00 PM
Grand Ballroom Salon D-H
Histological Improvements in VVA Patients with Intravaginal Prasterone (Intrarosa®): What do Aromatase Inhibitors Tell Us?
Intravaginal prasterone has been shown to reduce moderate to severe dyspareunia in postmenopausal patients. This presentation will not only offer an unprecedented insight into the histological improvements underlying the relief of these symptoms by Intrarosa®, but also investigate a potential role for androgens in the physiopathology of VVA.
Alain Dury, PhD
Director, Scientific Affairs & Alliance Manager, Endoceutics, Inc.